STOCK TITAN

AkzoNobel launches private notes offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Akzo Nobel N.V. commenced a private notes offering through subsidiary Akzo Nobel, Inc.; net proceeds are intended for general corporate purposes and may also refinance certain Axalta debt after completion of the proposed all-stock merger of equals. AkzoNobel and Axalta shareholders approved the merger on August 5, 2026, but it remains subject to required regulatory approvals and customary closing conditions. AkzoNobel will be the accounting acquirer under IFRS 3.

The unaudited pro forma figures assume the merger occurred on September 30, 2026 for the balance sheet and January 1, 2025 for the income statement. They show €10.882 billion in combined revenue and €199 million in profit for the nine months ended September 30, 2026, and €25.279 billion in combined assets as of September 30, 2026. These figures are illustrative, not forecasts, and exclude the planned divestitures of AkzoNobel’s European vehicle refinishing business and Axalta’s North American building products business.

Filing Explained

A ten percent change in AkzoNobel’s share price changes preliminary merger consideration and related goodwill by 639 million euros.

The private notes offering has commenced, but the notes and guarantee are unregistered; an expected registration-rights agreement would require commercially reasonable efforts to register exchange notes or, in some circumstances, resales.

If the still-pending all-stock merger completes, issuing the additional shares would reduce existing holders’ percentage ownership, absent offsetting changes. The pro forma financing assumes €900 million of cash on hand, previously issued notes of €600 million and €750 million, and additional debt for remaining needs; a bridge facility may be used if planned placements are incomplete or insufficient.

Pro forma combined revenue €10.882 billion Nine months ended September 30, 2026; assumes the merger occurred on January 1, 2025.
Pro forma combined profit €199 million Nine months ended September 30, 2026; assumes the merger occurred on January 1, 2025.
Pro forma basic earnings per share €0.58 per share Nine months ended September 30, 2026.
Pro forma combined total assets €25.279 billion As of September 30, 2026.
Preliminary purchase consideration €6.414 billion Preliminary estimate for the proposed merger.
Purchase consideration sensitivity €639 million A 10% fluctuation in AkzoNobel’s ordinary share price would change preliminary purchase consideration by this amount, with a corresponding change to goodwill.
New 2031 Senior Notes €600 million AkzoNobel issued the notes on March 25, 2026; they bear 4.000% interest and are due March 25, 2031.
New 2029 Senior Notes €750 million AkzoNobel issued the notes on June 16, 2026; they bear 3.625% interest and are due June 16, 2029.
pro forma condensed combined financial information financial
"unaudited pro forma condensed combined financial information"
acquisition method of accounting financial
"using the acquisition method of accounting in accordance with IFRS 3"
An accounting method used when one company obtains control of another; the acquirer records the purchase by measuring the fair value of the consideration it gives up, identifying and measuring the acquiree’s identifiable assets and liabilities at their fair values, and recognizing either goodwill for excess purchase price or a gain if the fair value of net assets exceeds consideration. Measurement-period adjustments are allowed to revise provisional amounts as more information becomes available; the method applies only when control is obtained and replaces earlier approaches that combined owners’ interests without fair-value measurement.
preliminary purchase price allocation financial
"the preliminary purchase price allocation reflected in the Pro Forma Financial Information"
goodwill financial
"Any excess of the purchase price over the net fair value of such assets and liabilities will be recorded as goodwill."
Goodwill is the extra value a buyer pays for a company above the measurable worth of its buildings, inventory and other tangible items, reflecting things like brand reputation, customer loyalty and expected future profits. Think of paying more for a café because of its famous name and regulars rather than its furniture alone. It matters to investors because changes in goodwill — for example a write-down if expected benefits don’t materialize — can reduce reported earnings and signal that past acquisitions aren’t delivering as hoped.
Rule 144A regulatory
"in accordance with Rule 144A under the Securities Act"
Rule 144A is a regulation that makes it easier for companies to sell private bonds to large investors without going through all the usual rules that apply to public sales. It matters because it helps companies raise money more quickly and privately, often attracting big investors looking for special deals.
registration rights agreement regulatory
"Pursuant to a registration rights agreement expected to be entered into in connection with the issuance of the notes"
A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue and profit does AKZOF’s pro forma financial information report?

Revenue was €10.882 billion and profit was €199 million for the nine months ended September 30, 2026. The unaudited pro forma statement assumes the merger had been completed on January 1, 2025, and the figures are illustrative rather than a projection of future results.

What may the AKZOF notes offering proceeds be used for?

Akzo Nobel, Inc., an AkzoNobel subsidiary, is issuing the notes, and net proceeds are intended for general corporate purposes and may also refinance Axalta debt after completion of the merger. The potential refinancing includes term loans due December 20, 2029 and Axalta senior notes of $500 million due 2027, $700 million due 2029, and $500 million due 2031.

What conditions remain before the AKZOF-Axalta merger can be completed?

The merger remains subject to required regulatory approvals and other customary closing conditions. Shareholders of both companies approved the transaction at meetings held on August 5, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

November 17, 2026

Commission File Number: 000-17444

 

Akzo Nobel N.V.

Christian Neefestraat 2

1077 WW Amsterdam

The Netherlands

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

  

 

 

EXPLANATORY NOTE

 

As previously disclosed, on November 18, 2025, Akzo Nobel N.V. (“AkzoNobel”) entered into a Merger Agreement (as amended by Amendment No. 1 to Merger Agreement, dated May 27, 2026, and Amendment No. 2 to Merger Agreement, dated July 23, 2026) with Axalta Coating Systems Ltd. (“Axalta”), pursuant to which, on the terms and subject to the conditions set forth therein, AkzoNobel and Axalta have agreed to combine their respective businesses in a merger of equals (the “Merger”), with AkzoNobel (upon completion of the Merger, “MergeCo”) serving as the combined company’s listed parent.

 

AkzoNobel today commenced a private offering of notes (the “Notes Offering”) by Akzo Nobel, Inc., a subsidiary of AkzoNobel (the “Notes Issuer”), the net proceeds of the Notes Offering are intended to be used for general corporate purposes and may also be used to refinance, from time to time, in whole or in part, (i) the term loans due December 20, 2029 issued and outstanding pursuant to the credit agreement, dated February 1, 2013, by and among Axalta Coating Systems Dutch Holding B.V., Axalta Coating Systems U.S. Holdings, Inc., Axalta Coating Systems U.S., Inc., Axalta, as borrowers, the lenders from time to time party thereto and Barclays Bank PLC, as administrative agent and collateral agent, as amended from time to time, and (ii) Axalta’s outstanding $500 million senior notes due 2027, (iii) Axalta’s outstanding $700 million senior notes due 2029 and/or (iv) Axalta’s outstanding $500 million senior notes due 2031, in each case following the completion of the Merger.

 

AkzoNobel’s offering memorandum for the Notes Offering incorporates by reference unaudited pro forma condensed combined financial information giving effect to the Merger and the related transactions, consisting of (i) the unaudited pro forma condensed combined balance sheet of MergeCo as of September 30, 2026, giving effect to the Merger and the related transactions as if they had been consummated on September 30, 2026, and the unaudited pro forma condensed combined statement of income of MergeCo for the nine months ended September 30, 2026, giving effect to the Merger and the related transactions as if they had been consummated on January 1 2025, in each case together with the notes thereto, and (ii) the unaudited pro forma condensed combined statement of income of MergeCo for the year ended December 31, 2025, giving effect to the Merger and the related transactions as if they had been consummated on January 1, 2025.

 

 

 

 

The notes and the guarantee in the Notes Offering have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act) except in transactions exempt from, or not subject to, the registration requirements of the Securities Act. Accordingly, the notes and the guarantee are being offered and sold only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act and outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act. Pursuant to a registration rights agreement expected to be entered into in connection with the issuance of the notes, the Notes Issuer and AkzoNobel will be required to use commercially reasonable efforts to file with the U.S. Securities and Exchange Commission and cause to become effective a registration statement relating to an offer to exchange the notes for new notes having terms substantially identical to the notes registered under the Securities Act, or, in certain circumstances, to register the resale of the notes.

 

This announcement does not constitute an offer to sell or the solicitation of an offer to buy the notes or any other security, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offers of the notes or the guarantee will be made only by means of a private offering memorandum.

 

This announcement is directed only at persons who (i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”), (iii) fall within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Financial Promotion Order or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 (“FSMA”)) in connection with the issue or sale of any notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). This announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

 

In any member state of the European Economic Area (the “EEA”), this announcement is only addressed to and directed at persons who are “qualified investors” within the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”). In the United Kingdom, any offer of the notes will be made pursuant to an exemption under the Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”) from the prohibition on offers of securities to the public. This announcement does not constitute an advertisement for the purposes of the Prospectus Regulation or a prospectus for the purposes of the POATRs.

 

The notes are not intended to be offered, sold, distributed or otherwise made available to, and should not be offered, sold, distributed or otherwise made available to, any retail investor in the EEA or the United Kingdom. No key information document required by Regulation (EU) No 1286/2014 (as amended) has been prepared, and no disclosure document required by the FCA Product Disclosure Sourcebook (“DISC”) has been or will be prepared, for offering, selling or distributing the notes or otherwise making them available to retail investors in the EEA or the United Kingdom, respectively.

 

Forward-Looking Statements

 

This announcement contains forward-looking statements, including statements regarding the proposed offering, the intended use of proceeds and the expected timing and completion of the Merger. These statements are based on current plans, estimates and expectations and are subject to risks, uncertainties and assumptions, many of which are outside the control of AkzoNobel, and actual results may differ materially from those expressed or implied. Undue reliance should not be placed on these statements, which speak only as of the date of this announcement, and AkzoNobel undertakes no obligation to update them, except as required by applicable law. Neither the content of AkzoNobel’s website nor any website accessible by hyperlinks on AkzoNobel’s website is incorporated in, or forms part of, this announcement.

 

 

 

The following exhibit is furnished herewith:

 

Exhibit Index

 

Exhibit Number Description of Exhibit
99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF AKZO NOBEL N.V. RELATING TO AKZO NOBEL N.V. AND AXALTA COATING SYSTEMS LTD. MERGER OF EQUALS

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Akzo Nobel N.V.

 

         
Date: November 17, 2026     By: /s/ Grégoire Poux-Guillaume
        Name: Grégoire Poux-Guillaume
        Title: Chief Executive Officer

 

Date: November 17, 2026     By: /s/ Maarten de Vries
        Name: Maarten de Vries
        Title: Chief Financial Officer

 

 

Exhibit 99.1

 

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF AKZO NOBEL N.V. RELATING TO AKZO NOBEL N.V. AND AXALTA COATING SYSTEMS LTD. MERGER OF EQUALS

 

Introduction

 

The following unaudited pro forma condensed combined financial information of Akzo Nobel N.V. (the “Pro Forma Financial Information”), including the unaudited pro forma condensed combined balance sheet as of September 30, 2026 and the unaudited pro forma condensed combined statement of income for the nine months ended September 30, 2026 of Akzo Nobel N.V. (“AkzoNobel” and, together with its subsidiaries, “AkzoNobel Group”), has been prepared to illustrate the effect of the proposed all-stock merger of equals (the “transaction”) between AkzoNobel and Axalta Coating Systems Ltd. (“Axalta” and, together with its subsidiaries, “Axalta Group”) pursuant to the merger agreement, originally dated as of November 18, 2025 and as amended on May 27, 2026 and July 23, 2026, by and between AkzoNobel and Axalta (the “Merger Agreement”), which was approved by shareholders of AkzoNobel and Axalta at their extraordinary general meeting and special general meeting, respectively, each held on August 5, 2026, and the completion of which remains subject to the receipt of the required regulatory approvals and satisfaction of other customary closing conditions. As part of obtaining the required regulatory clearances for the transaction, AkzoNobel has announced that it is planning to divest its European vehicle refinishing business, and Axalta has announced that it is planning to divest its North American building products business. These divestitures have not been reflected for purposes of the Pro Forma Financial Information. For more information about the transaction, see the section entitled “The Merger Agreement—Conditions to the Merger” in AkzoNobel’s registration statement on Form F-4 filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 27, 2026 (File No. 333-296290), as amended on June 18, 2026, and declared effective by the SEC on June 23, 2026, in connection with the transaction, including the proxy statement/prospectus filed with the SEC on June 24, 2026, and as supplemented from time to time (the “Form F-4”).

 

The Pro Forma Financial Information was derived from and should be read in conjunction with:

 

·the AkzoNobel Group unaudited condensed consolidated financial statements as of September 30, 2026 and for the nine months ended September 30, 2026, and the sections entitled “Financial Highlights,” “Performance Coatings,” “Decorative Paints” and “Alternative Performance Measures,” contained in AkzoNobel’s interim report for the nine months ended September 30, 2026, furnished with the SEC on Form 6-K on October 21, 2026 (File No. 000-17444); and

 

·the Axalta Group unaudited condensed consolidated financial statements as of September 30, 2026 and for the nine months ended September 30, 2026, and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contained in Axalta’s Quarterly Report on Form 10-Q for the nine months ended September 30, 2026, filed with the SEC on October 29, 2026 (File No. 001-36733).

 

The unaudited pro forma condensed combined balance sheet as of September 30, 2026 gives effect to the transaction as if it had occurred on September 30, 2026. The unaudited pro forma condensed combined statement of income for the nine months ended September 30, 2026 gives effect to the transaction as if it had occurred on January 1, 2025.

 

The Pro Forma Financial Information has been prepared in accordance with Article 11 of Regulation S-X, except for the 2025 annual period. The Pro Forma Financial Information should be read together with the accompanying notes. Such notes describe, amongst others, the basis, assumptions and estimates related to the adjustments to the Pro Forma Financial Information.

 

The Pro Forma Financial Information is not necessarily indicative of what the financial position or results of operations of AkzoNobel Group after giving effect to the transaction actually would have been had the transaction been completed as of the dates indicated. In addition, the Pro Forma Financial Information does not purport to project the future financial position or operating results of AkzoNobel and its subsidiaries, including Axalta and its subsidiaries, following completion of the transaction (“MergeCo Group”). The pro forma adjustments are based on the best information available at the time of the preparation of the relevant Pro Forma Financial Information and certain assumptions that AkzoNobel Group believes to be reasonable.

 

 

 

The Financing Transactions

 

As part of the Merger Agreement, it was agreed that AkzoNobel will declare and pay the pre-completion distribution (as defined below) to AkzoNobel’s shareholders prior to completion.

 

Furthermore, the consummation of the transaction will constitute a “Change of Control” under the Axalta credit agreement. Pursuant to the Merger Agreement, AkzoNobel agreed to, in consultation with Axalta, use reasonable best efforts to obtain funds to, among other things, refinance the Axalta 2029 dollar term loans due December 20, 2029 issued pursuant to the Axalta credit agreement (as defined below) (the “Axalta 2029 Dollar Term Loans”) prior to, or substantially concurrently with, consummation of the transaction (“completion”).

 

On March 25, 2026, AkzoNobel issued 4.000% fixed rate senior unsecured notes due March 25, 2031 in an aggregate principal amount of €600 million (the “New 2031 Senior Notes”), and on June 16, 2026, AkzoNobel issued 3.625% fixed rate senior unsecured notes due June 16, 2029 in an aggregate principal amount of €750 million (the “New 2029 Senior Notes” and, together with the New 2031 Senior Notes, the “New Senior Notes”) pursuant to AkzoNobel’s Euro Medium Term Note Programme.

 

AkzoNobel intends to finance the pre-completion distribution, as well as the required refinancing of the Axalta 2029 Dollar Term Loans through a combination of cash generated from operations, cash on hand and the placement of bonds and commercial paper (including the New Senior Notes). Should such placements not yet be completed prior to completion, or be in amounts insufficient to fund such items, a bridge financing facility may be put in place. As such and based on information known at the time of this report, AkzoNobel is reflecting the source of this funding as coming from cash on hand in the amount of €900 million, the New 2031 Senior Notes of €600 million, the New 2029 Senior Notes in the amount of €750 million with the remaining funds coming from the issuance of additional debt to fund the transaction financing prior to completion and for purposes of this report.

 

Accounting for the Transaction

 

The transaction will be accounted for as a business combination using the acquisition method of accounting in accordance with IFRS 3, Business Combinations (“IFRS 3”). IFRS 3 requires that one of the two companies in a transaction be designated as the acquirer for accounting purposes based on the evidence available. AkzoNobel will be treated as the acquiring entity for accounting purposes. In identifying AkzoNobel as the acquiring entity for accounting purposes, AkzoNobel and Axalta took into account the anticipated relative voting rights of all equity instruments of MergeCo (as defined below), the intended composition of the governing body and senior management of MergeCo and the relative size of the companies. In assessing the size of each of the companies, AkzoNobel’s and Axalta’s management evaluated various metrics, including, but not limited to, revenue, profit before taxation, total assets and market capitalization. Accordingly, AkzoNobel will record assets acquired, including identifiable intangible assets, and liabilities assumed from Axalta at their respective fair values at the completion date (as defined below). Any excess of the purchase price over the net fair value of such assets and liabilities will be recorded as goodwill.

 

The financial condition and results of operations of AkzoNobel Group after completion will reflect Axalta Group after completion, but will not be restated retroactively to reflect the historical financial condition or results of operations of Axalta Group. The earnings of AkzoNobel Group following completion will reflect acquisition accounting adjustments, including the effect of changes in the carrying value for assets and liabilities on depreciation expense, amortization expense and interest expense. Goodwill will not be amortized but will be tested for impairment at least annually, and all tangible and intangible assets including goodwill will be tested for impairment when certain indicators are present. If, in the future, MergeCo determines that tangible or intangible assets (including goodwill) are impaired, MergeCo would record an impairment charge at that time.

 

Basis of Pro Forma Presentation

 

The Pro Forma Financial Information appearing below does not consider any potential effects of changes in market conditions on revenues or expense efficiencies, among other factors. In addition, as explained in more detail in the accompanying notes, the preliminary allocation of the pro forma purchase price reflected in the Pro Forma Financial Information is subject to adjustment and may vary significantly from the actual purchase price allocation that will be recorded upon completion.

 

 

 

The Pro Forma Financial Information has been prepared based on the aforementioned historical consolidated financial statements and the assumptions and adjustments as described in the notes to the Pro Forma Financial Information. The pro forma adjustments reflect transaction accounting adjustments related to the transaction and the financing transactions, which are discussed in further detail below. Amounts presented reflect the accounting for the transaction. These pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing the Pro Forma Financial Information. Therefore, the Pro Forma Financial Information is presented for illustrative purposes only and does not purport to represent MergeCo Group’s consolidated results of operations or consolidated financial position that would actually have occurred had the transaction been consummated on the dates assumed or to project MergeCo Group’s consolidated results of operations or consolidated financial position for any future date or period.

 

In addition, for purposes of the Pro Forma Financial Information, the applicable historical financial statements of Axalta Group have been reclassified to align to the financial statement presentation of AkzoNobel Group, and preliminarily adjusted for material accounting policy differences between U.S. generally accepted accounting principles (“U.S. GAAP”) and IFRS Accounting Standards as issued by the International Accounting Standards Board (“IFRS”) as applied by AkzoNobel Group identified to date.

 

The Pro Forma Financial Information is presented for illustrative purposes only and does not reflect the costs of any management adjustments, including integration activities or cost savings or synergies that may be achieved because of the transaction.

 

AkzoNobel Group and Axalta Group have not had any material relationships prior to the transaction. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.

 

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF SEPTEMBER 30, 2026

 

(€ millions, unless otherwise stated)

AkzoNobel Group
Historical
As Reported (IFRS)

Axalta Group
Historical
As Adjusted IFRS)

Transaction Accounting Adjustments

 

Transaction Financing Adjustments

 

Pro Forma
Combined

Convenience Translation

    (Note 2)           ($)
Assets                
Non-current assets                
Intangible assets  3,544  2,604 4,144 (A)      10,292  11,685
Property, plant and equipment  2,043  1,017 584 (A)      3,644  4,137
Right-of-use assets  280  139          419  476
Other non-current assets

1,744

394

 

 

 

 

2,138

2,428

Total non-current assets

7,611

4,154

4,728

 

–

 

16,493

18,726

Current assets                
Inventories  1,639  748 162 (A)      2,549  2,894
Trade and other receivables  2,651  1,288          3,939  4,472
Current tax assets  191  45          236  268
Short-term investments  266 –          266  302
Cash and cash equivalents  3,146  577 (159) (B) 1,102 (E)  1,281  1,454
      (2,236) (C) (1,116) (F)    
      (33) (D)        
Assets held for sale

515

–

 

 

 

 

515

585

Total current assets

8,408

2,658

(2,266)

 

(14)

 

8,786

9,975

Total assets

16,019

6,812

2,462

 

(14)

 

25,279

28,701

Equity and Liabilities                
Equity                
Shareholders' equity 4,853 2,309  (2,309) (A)     8,856 10,054
       6,414 (A)        
       (159) (B)        
       (2,236) (C)        
       (16) (D)        
Non-controlling interests

166

40

(5)

(A)

 

 

201

228

Group equity

5,019

2,349

1,689

 

–

 

9,057

10,282

Noncurrent liabilities                
Provisions and deferred tax liabilities 1,133 450 790 (A)     2,373 2,694
Long-term borrowings

5,501

2,251

 

 

(1,099)

(F)

6,653

7,553

Total non-current liabilities

6,634

2,701

790

 

(1,099)

 

9,026

10,247

Current liabilities                
Short-term borrowings 1,001  483     1,102 (E) 2,569 2,917
          (17) (F)    
Trade and other payables 2,941  1,197         4,138 4,698
Current tax liabilities 139  53         192 219
Current portion of provisions 149  29 (17) (D)     161 184
                 
Liabilities held for sale

136

–

 

 

 

 

136

154

Total current liabilities

4,366

1,762

(17)

 

1,085

 

7,196

8,172

Total equity and liabilities

16,019

6,812

2,462

 

(14)

 

25,279

28,701

 

 

 

The accompanying notes are an integral part of this Pro Forma Financial Information.

 

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF INCOME FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026

 

(€ millions, unless otherwise stated)

AkzoNobel Group
Historical
As Reported

(IFRS)

Axalta Group
Historical
As Adjusted (IFRS)

Transaction Accounting Adjustments

 

Transaction Financing Adjustments

 

Pro Forma Combined

Convenience Translation

    (Note 2)           ($)
Continuing operations                
Revenue 7,513 3,369         10,882 12,355
Cost of sales

(4,433)

(1,798)

(43)

(AA)

 

 

(6,274)

(7,123)

Gross profit

3,080

1,571

(43)

 

–

 

4,608

5,232

Selling, general and administrative (SG&A) costs (2,453) (1,076) (92) AA)     (3,621) (4,111)
Others results

(272)

(79)

 

 

 

 

(351)

(399)

Operating income

355

416

(135)

 

–

 

636

722

Finance income and expenses (114) (101)     (69) (CC) (231) (262)
          53 (DD)    
Results from associates

26

1

 

 

 

 

27

31

Profit before tax

267

316

(135)

 

(16)

 

432

491

Income tax

(192)

(79)

34

(BB)

4

(BB)

(233)

(265)

Profit for the period

75

237

(101)

 

(12)

 

199

226

Attributable to                
Shareholders of the company 56 236 (101)   (12)   179 203
Non–controlling interests

19

1

 

 

 

 

20

23

Profit for the period

75

237

(101)

 

(12)

 

199

226

Weighted average number of common shares                
Basic 171.3 213.9         311.2 311.2
Diluted 171.3 214.8         311.8 311.8
Earnings per share                
Basic 0.32 1.10         0.58 0.65
Diluted 0.31 1.10         0.57 0.65

 

The accompanying notes are an integral part of this Pro Forma Financial Information.

 

 

 

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

1. Basis of Presentation

 

The pro forma adjustments have been prepared as if completion had occurred on September 30, 2026 in the case of the unaudited pro forma condensed combined balance sheet, and, in the case of the unaudited pro forma condensed combined statement of income, as if the transaction had been consummated on January 1, 2025.

 

The Pro Forma Financial Information has been prepared assuming the acquisition method of accounting in accordance with IFRS 3. Under this method, Axalta Group’s assets and liabilities will be recorded at their respective fair values. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing the Pro Forma Financial Information. Therefore, the Pro Forma Financial Information is presented for illustrative purposes only and does not purport to represent MergeCo Group’s consolidated results of operations or consolidated financial position that would actually have occurred had the transaction been consummated on the dates assumed or to project MergeCo Group’s consolidated results of operations or consolidated financial position for any future date or period.

 

2. Presentation Adjustments to Axalta Group’s Historical As Reported Financial Statements

 

Axalta Group’s historical balances were derived from their historical financial statements described above and are presented in accordance with U.S. GAAP and in the reporting currency of USD. The table below presents adjustments to align Axalta Group’s historical financial statements with AkzoNobel Group’s, which are presented in accordance with IFRS and in the reporting currency of EUR.

 

During the preparation of the Pro Forma Financial Information, AkzoNobel Group performed a preliminary review of Axalta Group’s financial information to identify differences in financial statement presentation and accounting policy differences as compared to the presentation of AkzoNobel Group. Based on the information currently available, certain adjustments have been made to Axalta Group’s historical financial statements to conform to AkzoNobel Group’s presentation. Upon consummation of the transaction, further review of Axalta Group’s financial statements may result in additional adjustments, which could be materially different from the amounts set forth in the Pro Forma Financial Information presented herein.

 

 

 

Refer to the table below for preliminary reconciliation of the historical financial information of Axalta Group to AkzoNobel Group’s presentation:

 

Unaudited Condensed Consolidated Balance Sheet as of September 30, 2026

Axalta Group Financial Statement Line

Axalta Group Historical Amount

Axalta Group Historical Amount

Reclassification

 

IFRS Conversion

 

Axalta Group Historical Reclassified Amount

AkzoNobel Group Financial Statement Line

(€ millions, unless otherwise stated) ($) (i) (ii)   (iii)      
Assets                
Current assets:                
Cash and cash equivalents 650 572 5 (a)     577 Cash and cash equivalents
Restricted cash 6 5 (5) (a)     —  
  — — 84 (b) (39) (b) 45 Current tax assets

Accounts and notes receivable,

net

1,366 1,203 85 (b)     1,288 Trade and other receivables
Inventories 849 748         748 Inventories
Prepaid expenses and other current assets

192

169

(169)

(b)    

—

 
Total current assets

3,063

2,697

—

 

(39)

 

2,658

Total current assets
  — — 36 (h) 103 (a) 139 Right-of-use assets

Property, plant and equipment,

net

1,319 1,162 (109) (c)     1,017 Property, plant and equipment
      (36) (h)        
Goodwill 1,762 1,552 (1,552) (d)     —  
Identifiable intangibles, net 1,056 930 122 (c)     2,604 Intangible assets
      1,552 (d)        
Other assets 547 482 (13) (c) (97) (a) 394 Other non-current assets
         

22

(b)    
Total assets

7,747

6,823

—

 

(11)

 

6,812

Total assets
Liabilities, Shareholders’ Equity                
Current liabilities:                
Accounts payable 780 687 510 (e)     1,197 Trade and other payables
  — — 53 (e)     53 Current tax liabilities
  — — 29 (e)     29 Current portion of provisions
Current portion of borrowings 519 457     26 (a) 483 Short-term borrowings
Other accrued liabilities 701 618 (592) (e) (26) (a) —  
Total current liabilities

2,000

1,762

—

 

—

 

1,762

Total current liabilities
Long-term borrowings 2,476 2,181     70 (a) 2,251 Long-term borrowings
Accrued pensions 225 198 (198) (g)     —  
Deferred income taxes 182 160 (160) (g)     —  
Other liabilities 198 174 358 (g) (70) (a) 450 Provisions and deferred tax liabilities
         

(12)

(b)    
Total liabilities

5,081

4,475

—

 

(12)

 

4,463

 
Commitments and contingent liabilities                
Shareholders’ equity:                
  — — 2,308 (f) 6 (a) 2,309 Shareholders’ equity
          (5) (b)    
Common shares 256 225 (225) (f)     —  
Capital in excess of par 1,637 1,442 (1,442) (f)     —  
Retained earnings 2,329 2,051 (2,051) (f)     —  
Treasury shares, at cost (1,202) (1,058) 1,058 (f)     —  
Accumulated other comprehensive loss

(400)

(352)

352

(f)    

—

 

Total Axalta shareholders’

equity

2,620 2,308 —   1   2,309  
Noncontrolling interests

46

40

       

40

Non-controlling interests
Total shareholders’ equity

2,666

2,348

—

 

1

 

2,349

 
Total liabilities and shareholders’ equity

7,747

6,823

—

 

(11)

 

6,812

Total equity and liabilities

 

 

Unaudited Condensed Consolidated Statement of Income for the Nine Months Ended September 30, 2026

Axalta Group Financial Statement Line

Axalta Group Historical Amount

Axalta Group Historical Amount

Reclassification

 

IFRS Conversion

 

Axalta Group Historical Reclassified Amount

AkzoNobel Group Financial Statement Line

(€ millions, unless otherwise stated) ($) (i) (ii)   (iii)      
Net sales 3,911 3,369         3,369 Revenue
Cost of goods sold 2,596 2,236 (420) (a) 18 (a) 1,798 Cost of sales
          (22) (a)    
          (14) (c)    
Selling, general and administrative expenses
614

529

420
(a)
14
(c)
1,076
Selling, general and administrative (SG&A) costs
      113 (b)        
Other operating charges 92 79         79 Others results
Research and development expenses 54 47 (47) (b)     –  
Amortization of acquired intangibles

77

66

(66)

(b)    

–

 
Income from operations

478

412

–

 

4

 

416

Operating income
  – – 97 (c) 4 (a) 101 Finance income and expenses
Interest expense, net 112 97 (97) (c)     –  
Other expense (income), net (1) (1) 1 (c)     –  
 

–

–

(1)

(c)    

(1)

Results from associates
Income before income taxes 367 316 –   –   316 Profit before tax
Provision for income taxes

92

79

       

79

Income tax
Net income 275 237 –   –   237 Profit for the period
Less: Net income attributable to noncontrolling interests


1


1

       


1

Non-controlling interests
Net income attributable to common shareholders


274


236


–

 


–

 


236

Shareholders of the company
Weighted average number of common shares                
Basic 213.9           213.9  
Diluted 214.8           214.8  
Earnings per share                
Basic 1.28           1.10  
Diluted 1.28           1.10  

 

(i)The financial statements of Axalta Group have been translated into EUR for the purposes of presentation in the Pro Forma Financial Information using the following exchange rates:

 

a)The spot rate as of September 30, 2026 of $1.00 to €0.88 for the unaudited pro forma condensed combined balance sheet as of September 30, 2026.

 

b)The average exchange rate for the period January 1, 2026 through September 30, 2026 of $1.00 to €0.86 for the unaudited pro forma condensed combined statement of income for the nine months ended September 30, 2026.

 

(ii)Reflects reclassification adjustments to conform Axalta Group’s historical balances to the financial statement presentation of AkzoNobel Group.

 

·Unaudited Condensed Consolidated Balance Sheet Impact:

 

(a)Represents the reclassification of historical Axalta Group’s restricted cash to cash and cash equivalents.

 

(b)Represents the reclassification of historical Axalta Group’s accounts and notes receivable, prepaid expenses and other current assets to trade and other receivables and current tax assets.

 

(c)Represents the reclassification of historical Axalta Group’s capitalized software and cloud computing arrangements within property, plant and equipment and other assets to intangible assets.

 

(d)Represents the reclassification of historical Axalta Group’s goodwill to intangible assets.

 

 

 

(e)Represents the reclassification of historical Axalta Group’s other accrued liabilities to trade and other payables, current tax liabilities and current portion of provisions.

 

(f)Represents the aggregation of historical Axalta Group’s common shares, capital in excess of par, retained earnings, treasury shares and accumulated other comprehensive loss to shareholders’ equity.

 

(g)Represents the reclassification of historical Axalta Group’s accrued pensions and deferred income taxes and other current liabilities to provisions and deferred tax liabilities.

 

(h)Represents the reclassification of historical Axalta Group’s finance leases within property, plant and equipment to right-of-use assets.

 

·Unaudited Condensed Consolidated Statement of Income Impact:

 

(a)Represents the reclassification of certain amounts of historical Axalta Group’s cost of sales to selling, general and administrative costs, primarily related to the costs of outbound logistical services as well as costs related to other functional costs supporting manufacturing.

 

(b)Represents the reclassification of historical Axalta Group’s research and development expenses and amortization of acquired intangibles to selling, general and administrative costs.

 

(c)Represents the reclassification of historical Axalta Group’s interest expense, net, and other expense (income), net to finance income and expenses and, where applicable, results from associates.

 

(iii)The historical consolidated financial statements of Axalta Group have been converted from U.S. GAAP to IFRS, applying AkzoNobel Group’s IFRS accounting policies.

 

Based on a preliminary review performed by AkzoNobel Group of Axalta Group’s historical consolidated financial statements, the following adjustments have been made to reflect Axalta Group’s historical consolidated balance sheet and consolidated statement of income on an IFRS basis for the purposes of the Pro Forma Financial Information.

 

a)Leases: Under U.S. GAAP, lessees are required to classify their leases as either finance leases or operating leases. Under IFRS, however, lessees apply a single lease accounting model that is broadly similar to the finance lease model under U.S. GAAP. As a result, the following adjustments have been made for the Axalta Group’s operating lease under IFRS.

 

·Unaudited Condensed Consolidated Balance Sheet Impact: Reflects the reclassification of operating lease right-of use-assets presented within Other assets to Right-of-use assets. Further, reflects the reclassification of operating lease liabilities presented within Other accrued liabilities and within Other liabilities to Short-term borrowings and Long-term borrowings, respectively.

 

  As of September 30, 2026
  (€ millions)
Decrease in Other assets 97
Increase in Shareholders’ equity 6
Increase in Right-of-use assets 103
Decrease in Other accrued liabilities 26
Increase in Short-term borrowings 26
Decrease in Other liabilities 70
Increase in Long-term borrowings 70

 

 

§Unaudited Condensed Consolidated Statement of Income Impact: Reflects the recognition of depreciation on right-of-use assets within Cost of sales related to operating leases which have been reclassified to financing leases with IFRS. Further, reflects the derecognition of operating lease cost within Cost of sales related to leases which have been reclassified to Right-of-use assets and recognition of incremental Finance expense on lease liabilities.

 

  For the Nine Months Ended September 30, 2026
  (€ millions)
Increase in Cost of sales 18
Decrease in Cost of sales 22
Increase in Finance expenses 4

 

b)Taxes on Intra-Entity Transfers of Inventories: Under U.S. GAAP, the tax effect of intra-entity transfers of inventories are deferred until the related inventories are sold or disposed of, and no deferred taxes are recognized for the difference between the carrying value of the inventories in the consolidated financial statements and the tax basis of the inventories in the buyer’s tax jurisdiction. In addition, the tax paid or payable from the intra-entity transfer is deferred upon consolidation and is not included in tax expense until the inventories are sold to an unrelated third party. Under IFRS, there is no exception for recognizing such tax consequences of intra-entity transfers of inventory. The following adjustments have been made to Axalta Group’s tax balances under IFRS:

 

  As of September 30, 2026
  (€ millions)
Decrease in Current tax assets 39
Increase in Other non-current assets 22
Decrease in Provisions and deferred tax liabilities 12
Decrease in Shareholders’ equity 5

 

c)Inventory: Under U.S. GAAP, inventory write-offs of finished goods are reflected within Cost of sales; however, AkzoNobel Group reflects these charges within Selling, general and administrative costs, which is allowable under IFRS. As a result, the following adjustments have been made for the Axalta Group’s inventory write-offs under IFRS.

 

  For the Nine Months Ended September 30, 2026
  (€ millions)
Decrease in Cost of sales 14
Increase in Selling, general and administrative costs 14

 

3. Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2026

 

(A)Reflects purchase price consideration as well as the purchase price allocation adjustments to record Axalta Group’s assets and liabilities at estimated fair value based on the consideration conveyed.

 

The preliminary purchase price was allocated among the identified assets to be acquired, based on a preliminary analysis. Goodwill is expected to be recognized as a result of the transaction, which represents the excess of the fair value of consideration over the fair value of the underlying net assets of Axalta Group. This was considered appropriate based on the determination that the transaction would be accounted for under the acquisition method under IFRS 3. The deferred income taxes represent the deferred tax impact associated with the incremental differences in book and tax basis created from the preliminary purchase price allocation. Deferred taxes associated with estimated fair value adjustments were calculated using the weighted average statutory income tax rate of 25.2%. The estimates of fair value are based upon preliminary valuation assumptions, and are believed to be reasonable, but are inherently uncertain and unpredictable. As a result, actual results may differ from estimates, and the difference may be material.

 

 

 

The following is a preliminary estimate of the assets acquired and the liabilities assumed by AkzoNobel Group in the transaction, reconciled to the estimated purchase consideration:

 

Net Assets Identified Preliminary Estimate of Fair Value
   (€ millions) 
Intangible assets(1)  6,748 
Property, plant and equipment(2)  1,601 
Right-of-use assets  139 
Other non-current assets  394 
Inventories(3)  910 
Trade and other receivables  1,288 
Current tax assets  45 
Cash and cash equivalents  577 
Non-controlling interests  (35)
Provisions and deferred tax liabilities  (1,240)
Short-term borrowings  (483)
Long-term borrowings  (2,251)
Trade and other payables  (1,197)
Current tax liabilities  (53)
Current portion of provisions  (29)
Total Net Assets Identified  6,414 
Value Conveyed    
     Equity Consideration(4)  6,378 
       Stock-based Compensation(5)  36 
Total Preliminary Purchase Consideration  6,414 

 

 

(1)Intangible assets were comprised of the following:

 

Asset type  Fair value  Weighted Average Remaining Useful Life  Valuation methodology
    (€ millions)       
Customer relationships    2,133   17.2 years  Multi-period excess earnings
Technology    617   10.0 years  Relief-from-royalty
Brand names    558   21.2 years  Relief-from-royalty
Software    125   10.0 years  Cost approach
Goodwill    3,315   N/A  IFRS 3
Total intangible assets    6,748       

 

 

(2)The property, plant and equipment fair value was primarily related to building and improvements, which accounted for 28% of the balance, and machinery and equipment, which accounted for 48% of the balance. These asset groups in AkzoNobel Group’s property, plant and equipment are included within the subcategory of land and buildings and plant equipment and machinery, respectively. The estimated weighted average remaining useful life of building and improvements and machinery and equipment was 17 years and 4.7 years, respectively.

 

(3)Reflects the fair value of inventories as a result of the transaction. Raw materials inventory is assumed to be at market value, and the adjustment is related to finished products and semi-finished products. The fair value of finished products and semi-finished products to be acquired in the transaction is determined based on an analysis of estimated future selling prices, costs of disposal, holding costs and estimated profit allowance for the selling effort of the acquiring entity based on profit for similar products.

 

(4)Equity consideration was calculated as 140 million shares of AkzoNobel Group ordinary shares to be issued to existing Axalta Group shareholders (i.e., Axalta Group’s outstanding common shares equal to 214 million as of September 30, 2026, multiplied by the exchange ratio of 0.6539), multiplied by €45.58, the adjusted per share value of AkzoNobel Group (i.e., calculated as the closing share price of AkzoNobel Group ordinary shares on October 23, 2026 equal to €58.62, multiplied by the AkzoNobel Group ordinary shares outstanding equal to 171 million (approximately) as of October 23, 2026, less the special dividend of €2,500 million net of paid dividends of €264 million, divided by AkzoNobel Group ordinary shares outstanding).

 

A 10% fluctuation in the share price of AkzoNobel ordinary shares would change the value of the preliminary purchase consideration reflected in the Pro Forma Financial Information by €639 million with a corresponding change to goodwill related to the transaction. The average opening and closing price for the pro forma period of January 1, 2025 through September 30, 2026 each varied from the share price used in calculating consideration by approximately 2%,. The maximum share price during this period varied by 15%, and the minimum share price during this period varied by 21%.

 

(5)Determination of consideration related to stock-based compensation required an allocation of the market-based measure under IFRS 3 between pre-combination compensation expense (i.e. purchase consideration) and post-combination compensation expense, which was determined using the adjusted per share value of AkzoNobel ordinary shares of €45.58 (as described in footnote 4 above) and the closing share price of Axalta common shares on October 23, 2026 of $34.14, or €30.50.

 

 

 

(B)Reflects €159 million of nonrecurring expenses related to estimated transaction costs. Of this amount, €88 million related to investment banking fees expected to be incurred by Axalta Group; this amount was not reflected as an income statement adjustment as it is not an expense of the accounting acquirer or of MergeCo. The remaining €71 million related to AkzoNobel Group’s estimated transaction costs, which are primarily comprised of investment banking fees, legal fees, accounting and audit fees, and other related advisory costs. The related income statement adjustment associated with AkzoNobel Group’s nonrecurring transaction costs is not reflected in the unaudited pro forma condensed combined statement of income for the nine months ended September 30, 2026.

 

(C)Reflects recognition of pre-completion distribution to be paid by AkzoNobel prior to the effective time (as defined below) of the transaction in an aggregate amount of €2.2 billion.

 

(D)Reflects the payment at completion of €33 million in cash retention bonuses to individuals at both AkzoNobel Group and Axalta Group. An additional €38 million will be payable six months after completion. AkzoNobel Group had accrued €20 million in respect of these retention bonuses on its balance sheet as of September 30, 2026. The related income statement adjustment is not reflected in the unaudited pro forma condensed combined statement of income for the nine months ended September 30, 2026.

 

(E)Reflects the issuance of additional debt in an aggregate principal amount of €1.1 billion, as described in the section entitled “The Financing Transactions.” The related income statement adjustment is reflected at adjustment (CC).

 

(F)Reflects the repayment of the Axalta 2029 Dollar Term Loans in an aggregate principal amount of €1.1 billion. The related income statement adjustment is reflected at adjustment (DD).

 

3. Adjustments to the Unaudited Pro Forma Condensed Combined Statement of Income for the Nine Months Ended September 30, 2026

 

(AA)Reflects the pro forma impacts related to the purchase price allocation discussed at adjustment (A). This includes the following impacts:

 

·Depreciation expense on Property, plant and equipment: Reflects an increase in depreciation expense recorded in Cost of sales in the amount of €43 million for the nine months ended September 30, 2026. This increase is primarily related to Buildings and improvements and Machinery and equipment and was calculated using the estimated weighted average remaining useful life of 17 years and 4.7 years, respectively.

 

·Amortization expense on Intangible assets: Reflects an increase in amortization expense recorded in selling, general and administrative costs of €92 million for the nine months ended September 30, 2026. This change is related to Customer relationships, Software, Technology and Brand names and was calculated using the estimated weighted average remaining useful lives of 17.2 years, 10.0 years, 10.0 years and 21.2 years, respectively.

 

(BB)Reflects the tax impact of all pro forma adjustments for the nine months ended September 30, 2026, calculated using the weighted average statutory income tax rate of 25.2%.

 

(CC)Reflects estimated interest expense related to (i) the issuance of additional debt, as presented at adjustment (E), calculated using an estimated interest rate of 6.3%; and (ii) the March and June senior notes, using fixed coupons of 4.0% and 3.6%, respectively, after deducting modeled interest already recorded on those notes. The June-note deduction assumes issuance on June 1, 2026. An increase or decrease of one-eighth of a percent in the interest rate related to the issuance of additional debt would not result in a significant change in interest expense for the nine months ended September 30, 2026.

  

(DD)Reflects the elimination of interest expense related to the Axalta 2029 Dollar Term Loans.

 

 

 

4. Unaudited Pro Forma Earnings per Share

 

Unaudited pro forma earnings per share calculations are based on the consolidated pro forma weighted average shares outstanding of AkzoNobel Group. The pro forma net income per share calculations have been performed for the nine months ended September 30, 2026, assuming the transaction occurred on January 1, 2025.

 

(in € millions except per share amounts)   For the Nine Months Ended September 30, 2026
Pro forma profit for the period    
Weighted average number of common shares   179
Number of shares:    
AkzoNobel Group   171
Axalta Group legacy shareholders.   140
Shares for basic earnings per share for the year   311
Effect of dilutive shares:    
AkzoNobel Group   –
Axalta Group legacy shareholders   1
Shares for diluted earnings per share   312
     
Pro forma earnings per share    
Basic   0.58
Diluted   0.57

 

definitions

 

As used herein, except where noted or the context otherwise requires:

 

·“AkzoNobel ordinary shares” refers to the common shares, par value €0.50 per share, of AkzoNobel.

 

·“Axalta common shares” refers to the common shares, par value of $1.00 per share, of Axalta.

 

·“Axalta credit agreement” refers to the credit agreement, dated February 1, 2013, by and among Axalta Coating Systems Dutch Holding B B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) organized and established under the laws of the Netherlands, having its corporate seat in Amsterdam, the Netherlands, registered with the Trade Register of the Netherlands under number 55948308, Axalta Coating Systems U.S. Holdings, Inc., a corporation organized under the laws of Delaware, Axalta Coating Systems U.S., Inc. a Delaware corporation, Axalta, the lenders from time to time party thereto and Barclays Bank PLC as administrative agent and collateral agent, as amended, restated, amended and restated, supplemented or otherwise modified from time to time.

 

·“Axalta shareholder” refers to a holder of Axalta common shares.

 

·“completion date” refers to the date of completion. AkzoNobel and Axalta expect to complete the transaction in early 2027, assuming the conditions to completion (described under the section of the Form F-4 in the section entitled “The Merger Agreement—Conditions to the Merger”) are satisfied.

 

·“effective time” refers to the time that the certificate of merger is issued by the Bermuda Registrar of Companies, or such other time and date as shall be set forth in the certificate of merger, in each case, with respect to the transaction.

 

·“MergeCo” refers to the successor by name change to AkzoNobel upon completion, which legal entity will be the parent entity of the combined group consisting of AkzoNobel Group and Axalta Group following completion of the transaction.

 

·“pre-completion distribution” refers to the special cash dividend, which AkzoNobel will declare and pay prior to the effective time (subject to applicable law and any applicable withholding tax), for an aggregate amount of €2.5 billion minus the aggregate amount of any regular annual and interim dividends declared by AkzoNobel with record dates in 2026 prior to the record date of the pre-completion distribution.

 

Filing Exhibits & Attachments

1 document

Keep reading